GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cyclically Adjusted PS Ratio

GKOS (Glaukos) Cyclically Adjusted PS Ratio : 13.91 (As of May. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cyclically Adjusted PS Ratio?

As of today (2025-05-28), Glaukos's current share price is $96.97. Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $6.97. Glaukos's Cyclically Adjusted PS Ratio for today is 13.91.

The historical rank and industry rank for Glaukos's Cyclically Adjusted PS Ratio or its related term are showing as below:

GKOS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.92   Med: 17.02   Max: 23.74
Current: 14.1

During the past years, Glaukos's highest Cyclically Adjusted PS Ratio was 23.74. The lowest was 9.92. And the median was 17.02.

GKOS's Cyclically Adjusted PS Ratio is ranked worse than
93.75% of 480 companies
in the Medical Devices & Instruments industry
Industry Median: 2.215 vs GKOS: 14.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glaukos's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.883. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.97 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Glaukos's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted PS Ratio Chart

Glaukos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 13.05 22.20

Glaukos Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.89 18.21 19.64 22.20 14.13

Competitive Comparison of Glaukos's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PS Ratio falls into.


;
;

Glaukos Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Glaukos's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=96.97/6.97
=13.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Glaukos's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.883/134.9266*134.9266
=1.883

Current CPI (Mar. 2025) = 134.9266.

Glaukos Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 6.097 100.684 8.171
201509 0.594 100.392 0.798
201512 0.630 99.792 0.852
201603 0.646 100.470 0.868
201606 0.789 101.688 1.047
201609 0.799 101.861 1.058
201612 0.895 101.863 1.186
201703 0.951 102.862 1.247
201706 1.203 103.349 1.571
201709 1.073 104.136 1.390
201712 1.204 104.011 1.562
201803 1.157 105.290 1.483
201806 1.235 106.317 1.567
201809 1.235 106.507 1.565
201812 1.500 105.998 1.909
201903 1.492 107.251 1.877
201906 1.607 108.070 2.006
201909 1.589 108.329 1.979
201912 1.196 108.420 1.488
202003 1.264 108.902 1.566
202006 0.712 108.767 0.883
202009 1.450 109.815 1.782
202012 1.624 109.897 1.994
202103 1.487 111.754 1.795
202106 1.686 114.631 1.985
202109 1.515 115.734 1.766
202112 1.561 117.630 1.791
202203 1.367 121.301 1.521
202206 1.535 125.017 1.657
202209 1.497 125.227 1.613
202212 1.492 125.222 1.608
202303 1.543 127.348 1.635
202306 1.665 128.729 1.745
202309 1.603 129.860 1.666
202312 1.685 129.419 1.757
202403 1.727 131.776 1.768
202406 1.887 132.554 1.921
202409 1.756 133.029 1.781
202412 1.897 133.157 1.922
202503 1.883 134.927 1.883

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (NYSE:GKOS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Glaukos Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653